Investor mix
11 investors on record; lead investors include Auriga Partners, GO CAPITAL, ACE Management.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 2 | 18% |
| Private equity | 3 | 27% |
| Accelerator & incubator | 1 | 9% |
| Other / undisclosed | 5 | 45% |
French, early-stage biotech developing bacteriophage treatments against multi-drug resistant bacterial infections
11 investors on record; lead investors include Auriga Partners, GO CAPITAL, ACE Management.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 2 | 18% |
| Private equity | 3 | 27% |
| Accelerator & incubator | 1 | 9% |
| Other / undisclosed | 5 | 45% |